Novo Nordisk’s daily semaglutide tablet offers an alternative to injectables as competition intensifies in the weight-loss drug market

The US Food and Drug Administration has approved an oral, once-daily version of Wegovy, marking a major milestone in the evolution of GLP-1–based obesity therapies. Developed by Novo Nordisk, the pill formulation uses the same active ingredient, semaglutide, as the widely prescribed weekly injectable Wegovy, giving patients and providers greater flexibility in treatment options.

The approval reflects growing demand for non-injectable weight-management therapies as GLP-1 drugs continue to reshape obesity care globally. Oral Wegovy is expected to appeal to patients who prefer tablets over injections, potentially broadening adoption across healthcare systems.

Clinical Performance and Therapeutic Profile

Data published in the New England Journal of Medicine showed that participants receiving the oral formulation achieved an average 13.6% reduction in body weight over 64 weeks, with nearly one-third of patients experiencing weight loss of 20% or more. Trial outcomes also indicated improvements in cardiovascular risk markers and physical activity levels comparable to those seen with injectable Wegovy.

Researchers noted that adherence remains a key consideration with daily oral therapies. Under optimal daily dosing conditions, weight loss with the pill was estimated to reach 16.6%, aligning closely with outcomes reported for injectable semaglutide.

The most frequently reported side effects included nausea and vomiting, consistent with the safety profile observed across the GLP-1 drug class.

Strategic Positioning in the GLP-1 Market

Novo Nordisk has prior experience in oral semaglutide through Rybelsus, approved in 2019 for type 2 diabetes. However, the newly approved Wegovy tablet uses a higher dose (25 mg), compared to Rybelsus’ 14 mg, enabling its effectiveness in obesity treatment.

The company has announced that the starting dose of 1.5 mg will be available in the US from early January 2026. Manufacturing is already underway at Novo Nordisk’s US facilities, with capacity expected to support market demand.

Competitive Landscape and Industry Implications

The approval comes amid intensified competition in the oral GLP-1 segment. Eli Lilly is advancing its own daily GLP-1 pill, orforglipron, which has demonstrated an average weight reduction of 12.4% in clinical trials. Unlike oral Wegovy, orforglipron does not require food or water restrictions, a potential differentiator. Eli Lilly has indicated plans to submit the drug for FDA review by the end of the year.

Industry analysts suggest pricing for oral and injectable GLP-1 therapies may remain broadly comparable, particularly when clinical efficacy is similar—an important consideration for payers, employers, and healthcare systems managing long-term obesity care costs.

Also read: Early-Stage Nipah Virus Vaccine Trials Signal Progress in Pandemic Preparedness

Expanding Treatment Choice in Obesity Care

For healthcare providers, insurers, and corporate health decision-makers, the FDA approval of oral Wegovy underscores a shift toward greater choice, convenience, and scalability in obesity management. As obesity increasingly intersects with chronic disease, cardiovascular risk, and workforce productivity, oral GLP-1 therapies may play a pivotal role in expanding access while sustaining clinical outcomes.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!